This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
BMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
by Zacks Equity Research
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
LQDAPositive Net Change UTHRNegative Net Change INSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
AZNNegative Net Change AMGNNegative Net Change RHHBYPositive Net Change JAZZNegative Net Change
biotechs medical pharmaceuticals
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
by Sundeep Ganoria
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
ABBVPositive Net Change SNYNegative Net Change JNJPositive Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
by Kanishka Das
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
PGENPositive Net Change MRKNegative Net Change INONegative Net Change
biotechs
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
by Zacks Equity Research
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
NVSNegative Net Change RGENPositive Net Change ANIKNegative Net Change IONSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
by Ekta Bagri
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
BMYNegative Net Change NVSNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
by Zacks Equity Research
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
NTLANegative Net Change REGNNegative Net Change RGENPositive Net Change ANIKNegative Net Change
biotechs
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
MRNANegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
by Zacks Equity Research
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
NVSNegative Net Change AMGNNegative Net Change IONSNegative Net Change
biotechnology biotechs medical pharmaceuticals